Added to YB: 2026-10-07
Pitch date: 2026-10-02
BBIO [bullish]
BridgeBio Pharma, Inc.
-0.4%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Market Cap
$12.9B
Pitch Price
$67.40
Price Target
102.50 (+53%)
Dividend
N/A
EV/EBITDA
-29.56
P/E
-18.44
EV/Sales
21.76
Sector
Biotechnology
Category
growth
$BBIO : BRIDGEing to a better tomorrow
BBIO: BridgeBio offers 53% upside to a $102.50 target from $66.91 as Attruby’s commercial ramp accelerates and the market assigns little value to the late-stage pipeline. Attruby delivered a 42% relative risk reduction in the composite of mortality and recurrent cardiovascular hospitalizations, while BBP-418 faces a November 2026 FDA decision. Regulatory rejection of surrogate biomarkers, payer restrictions and heavy cash burn could drive shares toward $43-$47.
Read full article (6 min)